Navigation Links
AbbVie to Host Second-Quarter Earnings Conference Call
Date:7/23/2014

xchange or transfer of securities in any jurisdiction in contravention of applicable law.

Additional Information and Where to Find it
In furtherance of a potential combination involving AbbVie, Shire plc and  AbbVie Private Limited ("Holdco"), Holdco intends to file with the SEC a registration statement on Form S-4 containing a Proxy Statement of AbbVie that will also constitute a Prospectus of Holdco relating to the Holdco Shares to be issued to AbbVie stockholders in the combination. In addition, AbbVie, Holdco and Shire may file additional documents with the SEC. INVESTORS AND SECURITY HOLDERS OF ABBVIE AND SHIRE ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS, AND OTHER DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE TRANSACTION CAREFULLY AND IN THEIR ENTIRETY, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Those documents, if and when filed, as well as AbbVie's and Holdco's other public filings with the SEC may be obtained without charge at the SEC's website at www.sec.gov, at AbbVie's website at www.abbvieinvestor.com. It is expected that the Holdco shares to be issued to Shire shareholders under a scheme of arrangement will be issued in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended, provided by Section 3(a)(10) thereof.

Participants in the Solicitation
AbbVie, its directors and certain of its executive officers may be considered participants in the solicitation of proxies in connection with the transactions contemplated by the Proxy Statement/Prospectus. Information about the directors and executive officers of AbbVie is set forth in its Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the SEC on February 21, 2014, and its proxy statement for its 2014 annual meeting of stockholders, which was filed with the SEC on March 24, 2014. Other information r
'/>"/>

SOURCE AbbVie
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AbbVie to Host Fourth-Quarter and Full-Year 2013 Earnings Conference Call
2. AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C
3. AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy
4. U.S. Gastroenterologists Have Increased Their TNF-alpha Inhibitor Use Since 2012, Especially for AbbVies Humira, as a Result of Its Recent Approval in Ulcerative Colitis
5. Financial Results, New Drug Applications, and Stock Price Movements - Research Report on Endo, Bristol-Myers Squibb, Express Scripts, AbbVie, and Incyte
6. AbbVie Reports Third-Quarter 2013 Financial Results
7. AbbVie Named a Science Top Employer
8. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
9. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
10. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
11. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 Braeburn Pharmaceuticals announced today ... focus beyond addiction and pain to include ... has acquired an implantable, six-month formulation of ... treatment of schizophrenia from Endo Pharmaceuticals. With ... to other potential applications of the implant ...
(Date:5/1/2015)... May 1, 2015 Pharmacyclics, Inc. (the "Company") ... the quarter ended March 31, 2015, as well as ... Inc., no conference call will be held. ... ended March 31, 2015 increased to $206 million from ... , Worldwide IMBRUVICA ® (ibrutinib) net product ...
(Date:5/1/2015)... May 1, 2015  Misonix, Inc. (NASDAQ: ... designs, manufactures and markets innovative therapeutic ultrasonic products ... cosmetic surgery, laparoscopic surgery and other surgical applications, ... for the third quarter fiscal year 2015 on ... a conference call that same day, Thursday, May ...
Breaking Medicine Technology:Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 27Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 28Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 29Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 30Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 31Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 32Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 33
... Oct. 16 Solos Endoscopy, Inc. (Pink Sheets: SNDY) ... received multiple purchase orders for its MammoView(TM) line ... Wheaton Franciscan Healthcare is one of the largest ... Endoscopy,s MammoView(TM) system employs advanced micro endoscopes and ...
... each state is responsible for its Women Infant Children program ... supplies. A state bid notification for breastpumps and supplies was ... needs further attention. The bid,s breastpump requirement was that the ... The state felt that it was acceptable for the pumps ...
Cached Medicine Technology:Solos Endoscopy, Inc. Receives Multiple Purchase Orders for its MammoView(TM) Product Line 2Do Women Have a Right to a Breastpump That Works? Asks Hygeia 2
(Date:5/3/2015)... " Bubbly Walrus ” was featured on ... look at the latest and coolest applications on the market ... AppWatch and technology expert, conducted the app review and shared ... , The best games to play on smartphones are the ... killing brain cells with a video game that just absorbs ...
(Date:5/3/2015)... 03, 2015 NuevaCare announced today that ... upcoming area seminars. The first event will take place ... Stroke Conference to be held at The Magnolia of ... May 13 during the Dementia Conference to be held ... seminars offer an excellent opportunity to learn about the ...
(Date:5/2/2015)... May 03, 2015 As one of ... the prestigious Safety and Health Achievement and Recognition Program ... to be chosen by the Illinois Department of Labor ... achieved and maintained SHARP certification by the Occupational Safety ... as Essentra has continued to meet or exceed all ...
(Date:5/2/2015)... May 02, 2015 ProText Kinetic 2 is ... in Final Cut Pro X. ProText Kinetic 2 features ... Final Cut Pro X . Easily create interactive ... Pixel Film Studios' ProText Kinetic 2. , Using ProText Kinetic ... staggering two ProText Kinetic presets in the FCPX timeline. ...
(Date:5/2/2015)... 2015 On Tuesday April 7th, the ... gathered to celebrate improvements in patient care. In 2014 ... (RVHP), had zero acquired ventilator associated infections, zero central ... ELCH was also recently named a Top Performer by ... ELCH credited the teamwork of staff from all departments ...
Breaking Medicine News(10 mins):Health News:An Application to Have Fun with Mathematics Was Featured on NewsWatch Television 2Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2
... same period in Fiscal 2008 -, ... otherwise noted),BELLEVILLE, ON, May 6 /PRNewswire-FirstCall/ - Bioniche ... Canadian biopharmaceutical company, today announced financial results for ... ending March 31, 2009. , "The year-to-date revenue ...
... (NYSE: GSK ) today announced that it has ... Wellbutrin XL (R) in the United States ... (NYSE, TSX: BVF), for $510 million (euro 340 million). ... United States.Generic competition to Wellbutrin XL began at ...
... Outside of Houston PHOENIX, May 6 Today ... D. Anderson Cancer Center announced they will create the M. ... leading provider of health care and the nation,s leading cancer ... level of cancer care in Arizona.Located at US 60 and ...
... for generous contribution to New York University College of Dentistry ... ... D.D.S. and his wife, Ellen Linhart, have established the New York ... Linhart’s alma mater. In honor of this act of philanthropy, New ...
... Max Muscle Sports Nutrition,s newest product innovation is L-Tox, for advanced ... along with protective and regenerative factors. , ... Anaheim, ... Administration (FDA) www.fda.gov issued a stop product use directive ...
... to the transition from in-patient to outpatient care for diabetes patients ... discussion on the Diabetes Best Practices Website provide up-to-date information and ... ... 6, 2009 -- "Diabetes Discharge planning is a national priority," says ...
Cached Medicine News:Health News:Bioniche Reports Fiscal 2009 Third Quarter 2Health News:Bioniche Reports Fiscal 2009 Third Quarter 3Health News:Bioniche Reports Fiscal 2009 Third Quarter 4Health News:Bioniche Reports Fiscal 2009 Third Quarter 5Health News:Bioniche Reports Fiscal 2009 Third Quarter 6Health News:Bioniche Reports Fiscal 2009 Third Quarter 7Health News:Bioniche Reports Fiscal 2009 Third Quarter 8Health News:Bioniche Reports Fiscal 2009 Third Quarter 9Health News:Bioniche Reports Fiscal 2009 Third Quarter 10Health News:GlaxoSmithKline to Divest US Rights for Wellbutrin XL(R) to Biovail for $510 Million 2Health News:Banner Health, M. D. Anderson Announce Cancer Care Facility for Arizona 2Health News:Banner Health, M. D. Anderson Announce Cancer Care Facility for Arizona 3Health News:Manhattan Dentist Inducted Into The Sir Harold Acton Society 2Health News:Max Muscle Sports Nutrition Offers Support for Hydroxycut Recall 2Health News:Max Muscle Sports Nutrition Offers Support for Hydroxycut Recall 3Health News:Diabetes Discharge Planning is this the latest Topic in Focus at the Diabetes Best Practices Website 2
Liquichek™ Homocysteine Control is a liquid control for monitoring homocysteine test procedures. This product can be used or methods such as HPLC and automated immunoassay procedures....
Bio-Rad's Liquichek™ D-dimer Control provides the laboratory with a liquid, trilevel, human plasma based control for the monitoring of D-dimer testing on most automated coagulation, chemistry a...
Lyphochek Diabetes Control is a human whole blood based product used to monitor hemoglobin fractions associated with diabetes, including Hemoglobins A1, A1C, F and Total Glycated Hemoglobin....
Lyphochek Hemoglobin A2 Control is a human whole blood based product designed to monitor the performance of automated and manual procedures for the measurement of hemoglobin variants, including Hemog...
Medicine Products: